Mercy partners in study with GRAIL for Galleri® MCED test on 50,000 Medicare beneficiaries.

Unusual Whales
2026.01.08 14:44
In St. Louis on January 8, 2026, Mercy announced their involvement in a research study to assess the effectiveness of GRAIL's Galleri® multi-cancer early detection (MCED) test on Medicare recipients. This three-year REACH study, identified by NCT05673018, aims to analyze the clinical benefits of the test and will involve a comparison of results from up to 50,000 Medicare beneficiaries.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer